EGFR and colorectal carcinoma: More importantly, the proposed combined therapeutic strategy showed the same efficacy in CRC PDX as the recent FDA and EMA approved therapy for BRAFV600E CRC of encorafenib (BRAFi) and cetuximab (anti-EGFR) [18].